Steven Seedhouse
Stock Analyst at Raymond James
(3.32)
# 990
Out of 4,944 analysts
173
Total ratings
44.05%
Success rate
3.28%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $64.72 | +26.70% | 20 | Aug 7, 2025 | |
| KRRO Korro Bio | Initiates: Overweight | $74 | $15.99 | +362.79% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $8.45 | +18.34% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $21.09 | +32.76% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $6.65 | +606.77% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.83 | +1,100.48% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $8.35 | +139.52% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $39.86 | +160.91% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.68 | +1,209.52% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $19.94 | +180.84% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $9.04 | +442.04% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $1.91 | +632.98% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $120.02 | -22.51% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $21.14 | +221.67% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $23.90 | +343.51% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.60 | +167.86% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $11.64 | +381.31% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.32 | +5,311.26% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $10.86 | +424.86% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.47 | +1,396.60% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.29 | +642.36% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $2.91 | +1,102.75% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $39.87 | -4.69% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $46.23 | +53.58% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.93 | +159.07% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $20.09 | +89.15% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.89 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.42 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $13.07 | +1,965.80% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $128.93 | - | 2 | Apr 23, 2020 |
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $64.72
Upside: +26.70%
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $15.99
Upside: +362.79%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $8.45
Upside: +18.34%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $21.09
Upside: +32.76%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $6.65
Upside: +606.77%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.83
Upside: +1,100.48%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $8.35
Upside: +139.52%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $39.86
Upside: +160.91%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.68
Upside: +1,209.52%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $19.94
Upside: +180.84%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $9.04
Upside: +442.04%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.91
Upside: +632.98%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $120.02
Upside: -22.51%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $21.14
Upside: +221.67%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $23.90
Upside: +343.51%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.60
Upside: +167.86%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $11.64
Upside: +381.31%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.32
Upside: +5,311.26%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $10.86
Upside: +424.86%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.47
Upside: +1,396.60%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.29
Upside: +642.36%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $2.91
Upside: +1,102.75%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $39.87
Upside: -4.69%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $46.23
Upside: +53.58%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.93
Upside: +159.07%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $20.09
Upside: +89.15%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $14.89
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.42
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $13.07
Upside: +1,965.80%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $128.93
Upside: -